Minnesota is currently home to 2090 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/07/2025
Locations: Site 107, Rochester, Minnesota
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Coordinated Reset Deep Brain Stimulation for Essential Tremor
NCT05897775
Recruiting
Deep brain stimulation (DBS) is a surgical procedure for the treatment of Essential Tremor (ET). A novel approach to current DBS approaches is called coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS that uses continuous high amplitude, high frequency stimulation. This study will evaluate the feasibility, safety and short-term efficacy of thalamic CR-DBS in upper extremity ET. The goal of this study is... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Essential Tremor, Upper Extremity Essential Tremor
Register for Updates
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
NCT06594445
Recruiting
This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hematopoietic stem cell transplantation, and are refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit. The hypothesis is GTB-3650 TriKE will induce nat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
NCT06498661
Recruiting
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not un... Read More
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
02/06/2025
Locations: Minneapolis VA Medical Center, Minneapolis, Minnesota
Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Register for Updates
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986
Recruiting
This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Gynecologic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
NCT06326216
Recruiting
This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Prostate Carcinoma
Register for Updates
A Study of Adipose Tissue in Adaptive Responses to Exercise
NCT06053125
Recruiting
The purpose of this research is to determine how exercise affects fat (adipose) tissue and how changes to adipose tissue that occur during and after exercise might improve health in aging and obesity.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Healthy, Obesity
Register for Updates
A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers
NCT05739149
Recruiting
The purpose of this research is to explore the use of high-resolution microvessel ultrasound imaging system to look for scarring and to monitor wound healing and to see if treatment affects the amount of tiny vessels and circulation around the wound.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Non-Healing Ulcer of Skin, Non-healing Wound, Lower Extremity Wound
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253
Recruiting
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Recurrent Squamous Cell Carcinoma
Register for Updates
A Prospective, Randomized Comparison of Drainage Techniques After One- or Two-Level Open Posterior Lumbar Decompression or Decompression and Fusion
NCT06820736
Recruiting
This project is being done to understand if a drain reduces recovery problems after surgery, such as infection or the need for more surgery.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/05/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Complications, Postoperative
Register for Updates
PACTAID App in Adults with Type 1 Diabetes to Help Manage Exercise
NCT06730906
Recruiting
The purpose of this trial is to test and refine the PACTAID smart phone application in adults with type 1 diabetes mellitus to help manage exercise while on automated insulin delivery systems with the goal of improving glycemic control during and after exercise as well as improving multiple other cardiovascular risk factors.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC
NCT06228924
Recruiting
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates